한글목차

세계의 병리학용 AI 시장 규모는 예측 기간 동안 15.4% 높은 CAGR로 확대될 전망이며, 2024년 8,280만 달러에서 2029년에는 1억 6,980만 달러에 이를 것으로 예측됩니다.

병리학용 AI는 특히 병리학용으로 설계된 인공지능(AI)의 개발, 전개, 이용으로 이루어진 헬스케어 산업의 분야를 가리킵니다. 임상 데이터, 게놈 정보, 질환의 진행은 이러한 AI 모델을 사용하여 분석할 수 있습니다. 이러한 AI 모델은 개인화된 치료 계획, 고위험 환자 식별, 의료 자원 배분 최적화를 지원합니다. AI는 고급 AI 알고리즘, 컴퓨터 비전, 기계 학습을 사용함으로써 병리 의사가 관련 정보를 추출하고 이미지를 분석하는 것을 돕습니다.

2023년 창약 부문은 병리학용 AI 시장에서 가장 큰 점유율을 차지했습니다. 이 주요 요인은 효율적이고 비용 대비 효과가 높은 의약품에 대한 수요가 높다는 것이며 병리학용 AI는 데이터 분석을 자동화하고 잠재적인 의약품을 보다 빨리 특정함으로써 창약 프로세스를 가속화하는데 도움이 되기 때문입니다. 게다가 하이 스루풋 스크리닝의 화상화 기술의 진보나, 위법 약물의 독물 검사에서 AI의 활용도, 이 시장의 추진력으로서 작용하고 있습니다. 게다가 기존의 방법은 매우 시간과 비용이 들기 때문에 시간과 비용의 절감은 매우 중요한 역할을 합니다. 병리학용 AI를 도입함으로써 보다 신속한 인사이트 및 의사결정이 가능해져 프로세스 합리화에 도움이 됩니다. 그 결과 프로세스가 보다 효율적이고 비용 효율적이 되며, 이 모든 요인이 맞물려 이 시장 성장의 촉매로 작용합니다.

제약 및 바이오 의약품 기업 부문은 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다. 제약 기업과 AI 프로바이더 간의 협력 관계의 고조는, AI의 급속한 채용을 촉진하고, 또, 기업은 의약품 개발과 혁신에 대해 경쟁력을 유지하기 위해서 AI 툴에 고액의 투자를 실시하고 있습니다. AI는 대규모 데이터셋 분석, 조직 샘플 패턴 파악, 치료 반응 예측을 통해 신약 개발 과정의 신속한 추적과 합리화에 도움을 주기 때문에 시간 소비를 줄이고 비용 대비 효과를 높여 보다 신속한 혁신으로 이어지고 있습니다. 바이오의약품 기업들은 병리학용 AI가 개별 포트폴리오에 대한 상세한 인사이트를 제공함으로써 개별화 의료 개발을 지원하기 때문에 AI 기반 디지털 병리학에 의존하고 있습니다.

본 보고서에서는 세계의 병리학용 AI 시장에 대해 조사했으며, 제공 제품별, 신경망별, 기능별, 이용 사례별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 서문
• 시장 역학
• 고객의 비즈니스에 영향을 미치는 동향 및 혼란
• 업계 동향
• 생태계 분석
• 밸류체인 분석
• 기술 분석
• 규제 분석
• 가격 분석
• Porter's Five Forces 분석
• 특허 분석
• 주요 이해관계자와 구매 기준
• 최종 사용자 분석
• 주된 회의와 이벤트(2024-2025년)
• 사례 연구 분석
• 투자 및 자금조달 시나리오
• 병리학용 AI : 비즈니스 모델
• 병리학용 AI에 대한 AI 및 생성형 AI의 영향
• 무역 분석

제6장 병리학용 AI 시장 : 제공 제품별

• 서문
• 엔드 투 엔드 솔루션
• 틈새 포인트 솔루션
• 기술
• 하드웨어
• 현미경
• 스캐너
• 스토리지 시스템

제7장 병리학용 AI 시장 : 신경망별

• 서문
• 컨벌루션 신경망(CNNS)
• 적대적 생성 네트워크(GANS)
• 리커런트 신경망(RNNS)
• 기타

제8장 병리학용 AI 시장 : 기능별

• 서문
• 이미지 분석
• 진단
• 워크플로우 관리
• 데이터 관리
• 예측 분석
• CDSS
• 자동 보고서 생성
• 품질 보증 도구

제9장 병리학용 AI 시장 : 이용 사례별

• 서문
• 창약
• 질병의 진단 및 예후
• 임상 워크플로우
• 트레이닝 및 교육

제10장 병리학용 AI 시장 : 최종 사용자별

• 서문
• 제약 및 바이오 의약품 기업
• 병원 및 검사 기관
• 학술연구기관

제11장 병리학용 AI 시장 : 지역별

• 서문
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제12장 경쟁 구도

• 서문
• 주요 진입기업의 전략 및 비책
• 수익 분석(2019-2023년)
• 시장 점유율 분석(2023년)
• 기업평가 매트릭스 : 주요 진입기업(2023년)
• 기업평가 매트릭스 : 스타트업 및 중소기업(2023년)
• 기업평가 및 재무지표
• 경쟁 시나리오

제13장 기업 프로파일

• 주요 진출기업
  • KONINKLIJKE PHILIPS NV
  • F. HOFFMANN-LA ROCHE LTD.
  • HOLOGIC, INC.
  • AKOYA BIOSCIENCES, INC.
  • AIFORIA TECHNOLOGIES PLC
  • INDICA LABS INC.
  • OPTRASCAN
  • IBEX MEDICAL ANALYTICS LTD.
  • MINDPEAK GMBH
  • TRIBUN HEALTH
  • TECHCYTE, INC.
  • DEEP BIO INC.
  • LUMEA INC.
  • VISIOPHARM
  • AETHERAI
  • AIOSYN
  • PAIGE AI, INC.
  • PROSCIA, INC.
  • PATHAI, INC.
  • TEMPUS LABS, INC.
• 기타 기업
  • KONFOONG BIOINFORMATION TECH CO., LTD.
  • DOMORE DIAGNOSTICS AS
  • VERILY LIFE SCIENCES, LLC
  • DEEPPATH
  • 4D PATH INC.

제14장 부록

영문목차

The global AI in Pathology market is expected to reach USD 169.8 million by 2029 from USD 82.8 million in 2024 at a high CAGR of 15.4% during the forecast period. AI in pathology refers to the healthcare industry's sector which comprises of development, deployment, and utilization of Artificial Intelligence (AI) designed for pathology applications specifically. Clinical data, genomic information, and disease progression can be analysed by using these AI models. These AI models assist in personalized treatment planning, identifying high-risk patients, and optimizing healthcare resource allocation. The AI helps and assists pathologists in extracting relevant information and analyzing images with the use of advanced AI algorithms, computer vision, and machine learning.

"The drug discovery segment accounted for the largest share in 2023, by use case."

In 2023, the drug discovery segment held the largest share of the AI in pathology market. The major factor behind this is the high demand for efficient and cost-effective drugs, as AI in pathology helps in accelerating the drug discovery process by automating the data analytics and identifying potential drug faster. In addition, the advancements in high throughput screenings imaging technologies and utilization of AI in toxicology testing for illicit drugs also act as a driving force for this market. Furthermore, the reduced time and costs play a very vital role as traditional methods are very time consuming and expensive as well, the introduction of AI in pathology helps in streamlining the process by enabling faster insights and decision making. Which in tun makes the process more efficient and cost effective, these all factors combined act as a catalyst for the growth of this market.

"Pharmaceutical and biopharmaceutical companies is the fastest growing end-user segment in the AI in pathology market."

The pharmaceutical and biopharmaceutical companies segment is projected to witness the highest growth rate during the forecast period. The growing collaboration between pharmaceutical companies and AI providers fuels rapid adoption of AI, also the companies are heavily investing in AI tools to stay competitive in drug development and innovation. As AI helps in fast tracking and streamlining the processes for drug discovery by analysing large datasets, identifying patterns in tissue samples, and predicting treatment responses, which reduces the time consumption and makes it cost effective, leading to faster innovations. The biopharmaceutical companies rely on AI-based digital pathology for majorly development of individualized medicine, as AI powered pathology aids the development of personalised medicine by providing detailed insights into individual portfolio.

"North America accounted for the largest share in 2023, in AI in pathology market."

In 2023, the North American region held the largest market share in the AI in pathology market due to several factors. The first and foremost being the high adoption of AI technology and strong investment in research and development driving the market growth. For instance, companies like Koninklijke Philips N.V. in 2023, invested nearly USD 895 million in R&D for diagnosis and treatment. On the other hand, the advanced healthcare infrastructre plays a very vital role in this market as there's a need of high tech machinery such as advanced microscopes and scanners. Morover, the large patient pool and data availability contributes in creating a large database, which can be further used to train the AI for greater accuracy and efficiency. This increasing focus on technoology, patient safety, and quality improvement, combined with technological advancements in medical devices, continues to drive the adoption of AI in pathology market in North America.

The break-down of primary participants is as mentioned below:

• By Company Type - Tier 1: 55%, Tier 2: 25%, and Tier 3: 20%
• By Designation - C-level: 50%, Director-level: 30%, and Others: 20%
• By Region - North America: 40%, Europe: 35%, Asia Pacific: 20%, RoW: 5%

Key Players in the AI in pathology Market

The key players functioning in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).

Research Coverage:

The report analyses the AI in pathology market. It aims to estimate the market size and future growth potential of various market segments based on by offerings, neural networks, use-case, end-user, by functions and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers (Rising strategic collaborations among market players, integration of AI in multiplex imaging, Rising cases of misdiagnoses, AI-augmented telepathology broadening access to specialized pathology services, and technological advancements in deep learning), restraints (High cost of digital pathology systems, the scarcity of AI expertise and unclear regulatory guidelines for medical software, and lack of interoperability with legacy systems), opportunities (Growing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease Progression) challenges (Lack of sufficient data to train AI algorithms, data privacy, and ethical concerns, interpretability of AI models) influencing the growth of the AI in pathology market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market.
• Market Development: Comprehensive information on the lucrative emerging markets, offering, neural networks, functions, use-case, end-user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in pathology market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in pathology market like Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 STUDY ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.5.2 SCOPE-RELATED LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AI IN PATHOLOGY MARKET OVERVIEW
• 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX
• 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER & COUNTRY
• 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Development of CNNs and advanced AI models
    • 5.2.1.2 Integration of AI into multiplex imaging
    • 5.2.1.3 Increasing cases of misdiagnoses in patients
    • 5.2.1.4 Benefits of AI-augmented telepathology
    • 5.2.1.5 Advancements in deep learning & image processing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of digital pathology systems
    • 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software
    • 5.2.2.3 Inadequate interoperability issues with legacy systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing demand for personalized medicine
    • 5.2.3.2 Integration of multi-omics data
    • 5.2.3.3 Predictive analytics for disease progression
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Insufficient data for AI algorithms
    • 5.2.4.2 Data privacy & ethical concerns
    • 5.2.4.3 Challenges associated with interpretability of AI models
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 INDUSTRY TRENDS
  • 5.4.1 EVOLUTION OF AI IN PATHOLOGY
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Machine learning and artificial intelligence
    • 5.7.1.2 Computer vision
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Cloud computing
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Telepathology
• 5.8 REGULATORY ANALYSIS
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY LANDSCAPE
    • 5.8.2.1 North America
      • 5.8.2.1.1 US
      • 5.8.2.1.2 Canada
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
      • 5.8.2.3.1 Japan
      • 5.8.2.3.2 China
• 5.9 PRICING ANALYSIS
  • 5.9.1 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • 5.9.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT OF NEW ENTRANTS
  • 5.10.2 THREAT OF SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
  • 5.11.2 JURISDICTION & TOP APPLICANT ANALYSIS
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 END-USER ANALYSIS
  • 5.13.1 UNMET NEEDS OF END USERS
  • 5.13.2 END-USER EXPECTATIONS
• 5.14 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY
  • 5.15.2 CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 AI IN PATHOLOGY MARKET: BUSINESS MODELS
• 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
  • 5.18.1 KEY USE CASES
  • 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.18.2.1 Case Study: Accelerated biomarker discovery and clinical trial optimization
  • 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.3.1 Drug discovery & development market
    • 5.18.3.2 Medical imaging & diagnostics market
  • 5.18.4 USERS READINESS AND IMPACT ASSESSMENT
    • 5.18.4.1 User readiness
      • 5.18.4.1.1 Pharmaceutical companies
      • 5.18.4.1.2 Biopharmaceutical companies
    • 5.18.4.2 Impact assessment
      • 5.18.4.2.1 User A: Pharmaceutical companies
        • 5.18.4.2.1.1 Implementation
        • 5.18.4.2.1.2 Impact
      • 5.18.4.2.2 User B: Biopharmaceutical companies
        • 5.18.4.2.2.1 Implementation
        • 5.18.4.2.2.2 Impact
• 5.19 TRADE ANALYSIS
  • 5.19.1 IMPORT DATA
  • 5.19.2 EXPORT DATA

6 AI IN PATHOLOGY MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
• 6.3 NICHE POINT SOLUTIONS
  • 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
• 6.4 TECHNOLOGY
  • 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL UPTAKE
• 6.5 HARDWARE
• 6.6 MICROSCOPES
  • 6.6.1 AUTOMATED ANALYSIS OF TISSUE SAMPLES FOR EFFECTIVE CONCLUSIONS TO FUEL UPTAKE
• 6.7 SCANNERS
  • 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
• 6.8 STORAGE SYSTEMS
  • 6.8.1 ABILITY TO PROVIDE STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH

7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

• 7.1 INTRODUCTION
• 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
  • 7.2.1 ABILITY TO PROVIDE HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
• 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
  • 7.3.1 DESIGNED FOR GENERATION OF ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
• 7.4 RECURRENT NEURAL NETWORKS (RNNS)
  • 7.4.1 ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL UPTAKE
• 7.5 OTHER NEURAL NETWORKS

8 AI IN PATHOLOGY MARKET, BY FUNCTION

• 8.1 INTRODUCTION
• 8.2 IMAGE ANALYSIS
  • 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
• 8.3 DIAGNOSTICS
  • 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
• 8.4 WORKFLOW MANAGEMENT
  • 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
• 8.5 DATA MANAGEMENT
  • 8.5.1 ADVANCEMENTS IN DATA INTEGRATION & PROCESSING TO BOOST DEMAND
• 8.6 PREDICTIVE ANALYTICS
  • 8.6.1 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
• 8.7 CDSS
  • 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
• 8.8 AUTOMATED REPORT GENERATION
  • 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
• 8.9 QUALITY ASSURANCE TOOLS
  • 8.9.1 RISING REGULATORY DEMANDS TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS

9 AI IN PATHOLOGY MARKET, BY USE CASE

• 9.1 INTRODUCTION
• 9.2 DRUG DISCOVERY
  • 9.2.1 TARGET IDENTIFICATION & SELECTION
    • 9.2.1.1 Analysis of molecular & histological data for biomarker discovery to fuel market
  • 9.2.2 TARGET VALIDATION
    • 9.2.2.1 Increasing demand for precision medicine to drive market
  • 9.2.3 HIT IDENTIFICATION & PRIORITIZATION
    • 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake
  • 9.2.4 HIT-TO-LEAD IDENTIFICATION
    • 9.2.4.1 Advancements in ML to support market growth
  • 9.2.5 LEAD OPTIMIZATION
    • 9.2.5.1 Growing focus on therapeutic efficacy to propel market
  • 9.2.6 CANDIDATE SELECTION & VALIDATION
    • 9.2.6.1 Critical requirement for regulatory approvals to drive market
• 9.3 DISEASE DIAGNOSIS & PROGNOSIS
  • 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
• 9.4 CLINICAL WORKFLOW
  • 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
• 9.5 TRAINING & EDUCATION
  • 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH

10 AI IN PATHOLOGY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
• 10.3 HOSPITALS & REFERENCE LABORATORIES
  • 10.3.1 INCREASING UPTAKE OF INFECTIOUS DISEASE DIAGNOSIS TO DRIVE MARKET
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 INCREASING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH

11 AI IN PATHOLOGY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 UK
    • 11.3.2.1 Increasing focus on drug discovery & development to boost demand
  • 11.3.3 GERMANY
    • 11.3.3.1 Availability of funding for AI initiatives to fuel uptake
  • 11.3.4 FRANCE
    • 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake
  • 11.3.5 ITALY
    • 11.3.5.1 Digital transformation and innovation in healthcare to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Workforce shortages to fuel market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing incidence of infectious & chronic diseases to fuel uptake
  • 11.4.3 JAPAN
    • 11.4.3.1 Advanced healthcare infrastructure to propel market
  • 11.4.4 INDIA
    • 11.4.4.1 Growing focus on healthcare digitization to boost demand
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Strategic investments for AI adoption to support market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growth in pharmaceutical R&D to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Increasing investments in expansion of technological expertise to support market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Offering footprint
    • 12.5.5.3 Use-case footprint
    • 12.5.5.4 End-user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS /SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 COMPANY VALUATION
  • 12.7.2 FINANCIAL METRICS
  • 12.7.3 BRAND/SOFTWARE COMPARISON ANALYSIS
• 12.8 COMPETITIVE SCENARIO
  • 12.8.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.8.2 DEALS
  • 12.8.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 MnM view
      • 13.1.1.3.1 Key strengths
      • 13.1.1.3.2 Strategic choices
      • 13.1.1.3.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 HOLOGIC, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product/Service approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 AKOYA BIOSCIENCES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 AIFORIA TECHNOLOGIES PLC
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 INDICA LABS INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches & approvals
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 OPTRASCAN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Other developments
  • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 MINDPEAK GMBH
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service approvals
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 TRIBUN HEALTH
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 TECHCYTE, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product/Service launches
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Other developments
  • 13.1.12 DEEP BIO INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 LUMEA INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 VISIOPHARM
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services offered
      • 13.1.14.2.1 Recent developments
      • 13.1.14.2.2 Product/Service launches
      • 13.1.14.2.3 Expansions
  • 13.1.15 AETHERAI
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
  • 13.1.16 AIOSYN
    • 13.1.16.1 Business overview
    • 13.1.16.2 Product/Services offered
      • 13.1.16.2.1 Product/Service launches
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
    • 13.1.16.4 Recent developments
      • 13.1.16.4.1 Other developments
  • 13.1.17 PAIGE AI, INC.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products/Services offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Product/Service launches & approvals
      • 13.1.17.3.2 Deals
      • 13.1.17.3.3 Other developments
  • 13.1.18 PROSCIA, INC.
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products/Services offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Product/Service launches & enhancements
      • 13.1.18.3.2 Deals
      • 13.1.18.3.3 Other developments
  • 13.1.19 PATHAI, INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products/Services offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Product/Service launches & approvals
      • 13.1.19.3.2 Deals
  • 13.1.20 TEMPUS LABS, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products/Services offered
    • 13.1.20.3 Recent developments
      • 13.1.20.3.1 Product/Service launches
• 13.2 OTHER PLAYERS
  • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
  • 13.2.2 DOMORE DIAGNOSTICS AS
  • 13.2.3 VERILY LIFE SCIENCES, LLC
  • 13.2.4 DEEPPATH
  • 13.2.5 4D PATH INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS